Matches in SemOpenAlex for { <https://semopenalex.org/work/W3175541417> ?p ?o ?g. }
Showing items 1 to 97 of
97
with 100 items per page.
- W3175541417 endingPage "A671" @default.
- W3175541417 startingPage "A671" @default.
- W3175541417 abstract "Abstract Primary aldosteronism (PA) is now considered the sole, often curable, cause of hypertension in 5-10% of patients. Yet there has been only one RCT, and practice has changed little since the advent of CT scanning. Adrenal vein sampling (AVS) and adrenalectomy remain the standard, invasive interventions, leading to a 50% reduction in pill count as the average clinical improvement. Study Design In MATCH (Is Metomidate PET-CT superior to Adrenal vein sampling in predicting ouTCome from adrenalectomy in patients with primary Hyperaldosteronism), 142 patients, mean age 52, 32% female, 32% of African ancestry, 46% hypokalemic, had both AVS and 11C-metomidate PET CT (MTO) in random order, and were referred for surgery if aldosterone/cortisol ratio differed >4-fold between adequately cannulated adrenal veins, and/or SUVmax on MTO was >1.25 higher, in a definite tumour, than the opposite adrenal. The primary outcome is the proportion of patients in whom adrenalectomy achieved complete or partial biochemical or clinical cure, analysed hierarchically using PASO criteria.1 Anticipating ~50% incidence of unilateral PA, MATCH is powered to detect 25% superiority of MTO vs AVS, or non-inferiority at a lower-bound CI of -17%. Secondary outcomes include non-randomised comparison of outcomes between unilateral and bilateral PA; prediction of clinical outcome from the home BP (12 readings over 3 days) before and after starting spironolactone 100 mg od for 4 weeks; quality-of-life assessments; and analyses, by RNAseq, of genotype and transcriptomes of 56 of the CYP11B2-positive tumors, correlated with ethnicity and outcomes. Results: The analysis set is 75 patients who, on 31 Dec 2020, had undergone adrenalectomy with > 6 months follow-up. 67 patients (89%) had complete biochemical cure following PASO criteria,1 and 63 (84%) had complete or partial clinical cure. In 39 of the surgical patients, only one of MTO or AVS was scored as high-probability using criteria above. This score was confirmed at the multi-centre, Multi-Disciplinary Team (MDT) meeting which reviewed all MTO scans without knowledge of AVS. In the primary analysis, comparing accuracy of MTO and AVS by McNemar test, the 39 discordant results were allocated as a win to the positive investigation, if the patient was cured, or to the negative investigation, if not cured. 50/56 CYP11B2-positive tumors had a known mutation; the frequency was CACNA1D>KCNJ5>ATP1A1>ATP2B3>CTNNB1>GNAQ>CLCN2, differing between patients whose hypertension was completely or partially cured. Two other tumors had novel gene mutations. Several RNAseq transcripts varied with genotype and outcome, including some encoding measurable, secreted proteins. Full primary and secondary outcomes will be presented. 1. Williams TA, et al. Lancet Diabetes Endocrinol. 2017;5:689-699" @default.
- W3175541417 created "2021-07-05" @default.
- W3175541417 creator A5005240244 @default.
- W3175541417 creator A5006350937 @default.
- W3175541417 creator A5014814199 @default.
- W3175541417 creator A5016093000 @default.
- W3175541417 creator A5024670598 @default.
- W3175541417 creator A5028318426 @default.
- W3175541417 creator A5030991018 @default.
- W3175541417 creator A5035566438 @default.
- W3175541417 creator A5036659787 @default.
- W3175541417 creator A5037087757 @default.
- W3175541417 creator A5038848497 @default.
- W3175541417 creator A5038946529 @default.
- W3175541417 creator A5047568561 @default.
- W3175541417 creator A5050127225 @default.
- W3175541417 creator A5051210911 @default.
- W3175541417 creator A5058560355 @default.
- W3175541417 creator A5063847780 @default.
- W3175541417 creator A5067046310 @default.
- W3175541417 creator A5073106718 @default.
- W3175541417 creator A5076352375 @default.
- W3175541417 creator A5084682305 @default.
- W3175541417 date "2021-05-01" @default.
- W3175541417 modified "2023-10-16" @default.
- W3175541417 title "Primary Results From MATCH: A Randomised Controlled Trial in Primary Aldosteronism" @default.
- W3175541417 doi "https://doi.org/10.1210/jendso/bvab048.1369" @default.
- W3175541417 hasPublicationYear "2021" @default.
- W3175541417 type Work @default.
- W3175541417 sameAs 3175541417 @default.
- W3175541417 citedByCount "0" @default.
- W3175541417 crossrefType "journal-article" @default.
- W3175541417 hasAuthorship W3175541417A5005240244 @default.
- W3175541417 hasAuthorship W3175541417A5006350937 @default.
- W3175541417 hasAuthorship W3175541417A5014814199 @default.
- W3175541417 hasAuthorship W3175541417A5016093000 @default.
- W3175541417 hasAuthorship W3175541417A5024670598 @default.
- W3175541417 hasAuthorship W3175541417A5028318426 @default.
- W3175541417 hasAuthorship W3175541417A5030991018 @default.
- W3175541417 hasAuthorship W3175541417A5035566438 @default.
- W3175541417 hasAuthorship W3175541417A5036659787 @default.
- W3175541417 hasAuthorship W3175541417A5037087757 @default.
- W3175541417 hasAuthorship W3175541417A5038848497 @default.
- W3175541417 hasAuthorship W3175541417A5038946529 @default.
- W3175541417 hasAuthorship W3175541417A5047568561 @default.
- W3175541417 hasAuthorship W3175541417A5050127225 @default.
- W3175541417 hasAuthorship W3175541417A5051210911 @default.
- W3175541417 hasAuthorship W3175541417A5058560355 @default.
- W3175541417 hasAuthorship W3175541417A5063847780 @default.
- W3175541417 hasAuthorship W3175541417A5067046310 @default.
- W3175541417 hasAuthorship W3175541417A5073106718 @default.
- W3175541417 hasAuthorship W3175541417A5076352375 @default.
- W3175541417 hasAuthorship W3175541417A5084682305 @default.
- W3175541417 hasBestOaLocation W31755414171 @default.
- W3175541417 hasConcept C126322002 @default.
- W3175541417 hasConcept C126894567 @default.
- W3175541417 hasConcept C141071460 @default.
- W3175541417 hasConcept C168563851 @default.
- W3175541417 hasConcept C2776292634 @default.
- W3175541417 hasConcept C2776379505 @default.
- W3175541417 hasConcept C2778242168 @default.
- W3175541417 hasConcept C2778525890 @default.
- W3175541417 hasConcept C2780087391 @default.
- W3175541417 hasConcept C2780233176 @default.
- W3175541417 hasConcept C71924100 @default.
- W3175541417 hasConceptScore W3175541417C126322002 @default.
- W3175541417 hasConceptScore W3175541417C126894567 @default.
- W3175541417 hasConceptScore W3175541417C141071460 @default.
- W3175541417 hasConceptScore W3175541417C168563851 @default.
- W3175541417 hasConceptScore W3175541417C2776292634 @default.
- W3175541417 hasConceptScore W3175541417C2776379505 @default.
- W3175541417 hasConceptScore W3175541417C2778242168 @default.
- W3175541417 hasConceptScore W3175541417C2778525890 @default.
- W3175541417 hasConceptScore W3175541417C2780087391 @default.
- W3175541417 hasConceptScore W3175541417C2780233176 @default.
- W3175541417 hasConceptScore W3175541417C71924100 @default.
- W3175541417 hasIssue "Supplement_1" @default.
- W3175541417 hasLocation W31755414171 @default.
- W3175541417 hasOpenAccess W3175541417 @default.
- W3175541417 hasPrimaryLocation W31755414171 @default.
- W3175541417 hasRelatedWork W1524257451 @default.
- W3175541417 hasRelatedWork W1970298323 @default.
- W3175541417 hasRelatedWork W2034867134 @default.
- W3175541417 hasRelatedWork W2071264722 @default.
- W3175541417 hasRelatedWork W2073093077 @default.
- W3175541417 hasRelatedWork W2294623816 @default.
- W3175541417 hasRelatedWork W2375189450 @default.
- W3175541417 hasRelatedWork W2380664026 @default.
- W3175541417 hasRelatedWork W2382027553 @default.
- W3175541417 hasRelatedWork W4292605462 @default.
- W3175541417 hasVolume "5" @default.
- W3175541417 isParatext "false" @default.
- W3175541417 isRetracted "false" @default.
- W3175541417 magId "3175541417" @default.
- W3175541417 workType "article" @default.